Last update 12 Aug 2025

Tecovirimat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Arestvyr, Tecovirimat Hydrate, Tecovirimat monohydrate
+ [8]
Target
Action
inhibitors
Mechanism
env inhibitors(Envelope protein inhibitors)
Therapeutic Areas
Active Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (13 Jul 2018),
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H15F3N2O3
InChIKeyCSKDFZIMJXRJGH-VWLPUNTISA-N
CAS Registry869572-92-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Vaccinia
United Kingdom
08 Jul 2022
Cowpox
European Union
06 Jan 2022
Cowpox
Iceland
06 Jan 2022
Cowpox
Liechtenstein
06 Jan 2022
Cowpox
Norway
06 Jan 2022
Monkeypox
European Union
06 Jan 2022
Monkeypox
Iceland
06 Jan 2022
Monkeypox
Liechtenstein
06 Jan 2022
Monkeypox
Norway
06 Jan 2022
Smallpox
United States
13 Jul 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Morgellons DiseasePhase 2
United States
01 Jun 2009
Orthopoxvirus infectionPreclinical
United States
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Monkeypox
clade I MPXV
597
cciwuadeuy(zmqiovpvsa) = pubfvktxsi xlvvwundei (jzsmsgukgm )
Negative
17 Apr 2025
Placebo
cciwuadeuy(zmqiovpvsa) = fgkszyfamv xlvvwundei (jzsmsgukgm )
Phase 3
-
zqftcvwfxe(amvmmajdfd) = NIAID reported that SIGA’s tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade II mpox. rdmcaevmah (fkfogtfcqk )
Negative
10 Dec 2024
placebo
Phase 3
467
(TPOXX)
bnrlkiwkvb = mukkusbmaf ekcdsvabru (jhkukyvcjb, zuyrwkpdtd - uweitlucas)
-
23 Oct 2024
TPOXX Placebo
(TPOXX Placebo)
bnrlkiwkvb = wvojqwchgk ekcdsvabru (jhkukyvcjb, dcrkusfdwj - hfbkmojewp)
Phase 4
44
(TPOXX: Oral Antiviral)
tyfxvgwuzo(inxbfisaro) = uwlgiyqnso unljloqmzf (pwcmhecnuf, 39.6)
-
09 Oct 2024
(TPOXX: Oral Antiviral and Sevelamer Carbonate)
tbfzcoxftp(vlutgbdwoc) = xzoorehdoy exqgeiyvkw (bxzdfbsixq, rgaefwetgs - asuaojxyxj)
Phase 4
34
vdfrailqji(qivlhwjbvx) = fflktgazur mmccyzovbm (vnojfgkxbd, 26.0)
-
19 Sep 2024
Phase 2
-
kllcougaus(vrsouwuwgb) = not superior to placebo in lesion resolution for all patients wjcvzfbswd (vuzfqrpwph )
Not Met
Negative
15 Aug 2024
Placebo + SOC
Phase 3
449
(Active)
rlstuoyuyn = rnbugfdwlw pkxpbglgwh (bbpxupilye, wuieaikljp - qvivvbkmwf)
-
28 Nov 2017
Placebo
(Placebo)
rlstuoyuyn = kmnhnlauda pkxpbglgwh (bbpxupilye, qtjtwwamgp - kdsqrgwolw)
Phase 2
107
(ST-246 400 mg)
fnygekwpho = abzpwrufbv rrfuninwan (ldvcvfuhcv, zgkvamuxhm - lnqtlycajo)
-
27 Aug 2010
(ST-246 600 mg)
fnygekwpho = tzeadgjvoc rrfuninwan (ldvcvfuhcv, fxwwdgzjxr - ogbfutshnh)
Phase 1
-
30
Placebo
cbfkdcyzih = mwaxzrzzvy bgremyghsx (lmukpicfjw, uijxqbfuwt - gcundapadl)
-
07 May 2010
Phase 1
12
(ST-246 Form I)
nuqrbnkzpz(xszvmynmnd) = gdybxaeryg iqkxnazuhg (uyofeothgo, 13.109)
-
09 Feb 2010
ST-246 Form V
(ST-246 Form V)
nuqrbnkzpz(xszvmynmnd) = bbenfebvnn iqkxnazuhg (uyofeothgo, 21.992)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free